UK – UK-headquartered Iksuda Therapeutics has announced the closing of a $47m (£34m) financing round, with the funds to be used to support the advancement of its lead antibody drug…
Read MoreBiosphere tenant Iksuda Therapeutics raises $47m to reinforce Antibody Drug Conjugate pipeline
